Summary: Background: Early trials of long-term lenalidomide use reported an increased incidence of second primary malignancy (SPM). including acute myeloid leukaemia and myelodysplastic syndrome. Later. meta-analysis suggested the link to be secondary to lenalidomide in combination with melphalan. https://www.jmannino.com/best-catch-University-of-Miami-The-U-iPhone-14-Plus-Clear-Case-p36265-quick-deal/